期刊文献+

单次大剂量阿托伐他汀对不稳定性心绞痛患者血管内皮功能及Rho激酶活性的影响 被引量:12

Effect of a High Single Dose Atorvastatin on Endothelial Function and Rho Kinase Activity in Patients With Unstable Angina
下载PDF
导出
摘要 目的:通过观察单次大剂量阿托伐他汀对不稳定性心绞痛患者血管内皮功能及外周血白细胞Rho激酶活性的影响,探讨他汀改善不稳定性心绞痛患者血管内皮功能的可能机制。方法:入选2012-08至2014-02入住我院的不稳定性心绞痛患者78例,入院当日给予阿托伐他汀80 mg一次顿服。分别于服药前及服药后12 h以超声测反应性充血前后肱动脉内径(FMD)的变化,以免疫印迹法(Western Blot)测外周血白细胞肌球蛋白轻链磷酸酶的肌球蛋白结合亚单位(MYPT1)及在Thr853位上磷酸化的MYPT(1p-MYPT1^(Thr853))蛋白表达,以p-MYPT1^(Thr853)占总MYPT1的百分比表示Rho激酶的活性。结果:患者服用阿托伐他汀80 mg 12 h后,FMD较治疗前增加28.15%[(6.50±1.68)%vs(8.33±1.93)%,P<0.001],外周血白细胞Rho激酶活性较治疗前降低32.78%[(58.91±5.22)%vs(39.6±3.85)%,P=0.002]。结论:大剂量阿托伐他汀能快速改善不稳定性心绞痛患者的血管内皮功能,RhoA/Rho激酶通路抑制参与他汀类药物快速改善血管内皮功能的作用。 Objective: To explore the possible mechanism of statins improving endothelial function via observing the effect of a high single dose atorvastatin on endothelial dysfunction and peripheral blood leucocyte Rho kinase activity in patients with unstable angina (UA). Methods: A total of 78 consecutive UA patients admitted in our hospital from 2012-08 to 2014-02 were enrolled. The patients received a single dose of atorvastatin 80 mg on the day of admission. Flow-mediated vasodilation (FMD) of brachial artery was examined by high-resolution ultrasound at before and 12 hours after medication. Protein expression of phospho-speciifc Thr853-MYPT1 (p-MYPT1Thr853) and MYPT1 was measured by Western blot analysis; peripheral blood leukocyte Rho kinase activity was assayed by the proportion of phospho-Thr853 in myosin binding subunit of light chain phosphatase (MYPT1). Results: Compared to prior medication, with atorvastatin 80 mg for 12 hours, FMD was increased 28.15% as (6.50 ±1.68) % vs (8.33 ± 1.93) %,P〈0.001 and peripheral blood leucocyte Rho kinase activity was decreased 32.78% as (58.91 ± 5.22) % vs (39.6 ± 3.85 ) %,P=0.002.Conclusion: High dose atorvastatin could rapidly improve vascular endothelial dysfunction in UA patients. inhibiting of RhoA/Rho kinase pathway may involve in the effect of statins improving endothelial function.
出处 《中国循环杂志》 CSCD 北大核心 2016年第8期746-749,共4页 Chinese Circulation Journal
基金 2011年大连市医学卫生科学技术研究项目
关键词 阿托伐他汀 内皮 血管 RHO激酶 心绞痛 不稳定型 Atorvastatin Endothelial function Rho kinase Unstable angina
  • 相关文献

参考文献12

  • 1Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest, 2002, 110: 285-288.
  • 2Omori H, Nagashima H, Tsurumi Y, et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol, 2002, 54: 395-399.
  • 3Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res, 2003, 93: e98-e103.
  • 4Kono Y, Fukuda S, Shimada K, et al. Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin:reactive hyperemia peripheral arterial tonometric study. Drug Des Devel Ther, 2013, 7: 369-374.
  • 5李建军.他汀类药物非调脂作用及其机制(续9-2)[J].中国循环杂志,2011,26(3):233-234. 被引量:4
  • 6Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998, 97: 1129-1135.
  • 7Liu B, Zhang JY, Cao HM, et al. Effect of rosuvastatin on ROCK activity, endothelial function, and inflammation in Asian patients with atherosclerosis. Intern Med, 2012, 51:1177-1182.
  • 8Nohria A, Prsic A, Liu PY, et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis, 2009, 205: 517-521.
  • 9刘洋,李浪,苏强,周游,王江友,孙羽涵,杨栋.强化阿托伐他汀对不稳定性心绞痛患者冠状动脉介入治疗术后CD4+T淋巴细胞微小核糖核酸-21表达的影响[J].中国循环杂志,2014,29(1):26-30. 被引量:25
  • 10Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Col! Cardiol, 2009, 54: 558-565.

二级参考文献22

  • 1Kriszbacher I, Koppan M, Bodis J, et al. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 2005, 353: 429-430.
  • 2Pauley KM, Satoh M, Chan AL, et al. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther, 2008, 10: R101.
  • 3Sheedy FJ, Palsson-McDermott E, Hcnnessy E J, et al. Negative suppressor PDCD4 by the microRNA miR-21 regulation of TLR4 via targeting of the proinftammatory tumor. Nat Imnmnol, 2011, 11 : 141-147.
  • 4Zhong WW, Hal FL, Ji FS, et al. Inductive microRNA-21 impairs anti-mycobacterial responses by targeting IL-12 and Bcl-2. FEBS Letters, 2012, 586: 2459-2467.
  • 5Sawanta DV, Wu H, Kaplan MH, et al. The Bcl6 target gene microRNA-21 promotes Th2 differentiation by a T cell intrinsic pathway. Mol Immunolo, 2013, 54: 435-442.
  • 6Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coil Cardiol, 2007, 49: 1272- 1278.
  • 7Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem, 1985, 150: 76-85.
  • 8Saadeddin SM, Habbab MA, Sobki SH, et al. Minormyocardial injury after elective uncomplicated successful PTCA with or without stenting: detection by cardiac troponins. Catheter Cardiovasc Interv, 2001, 53: 188-192.
  • 9Methe H, Brunner S, Wiegand D, et al. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coil Cardiol, 2005, 45: 1939-1945.
  • 10Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy. Am J Pathol, 2007, 170: 1831-L840.

共引文献27

同被引文献96

引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部